BR112021010634A2 - Anticorpos antiperiostina e usos dos mesmos - Google Patents

Anticorpos antiperiostina e usos dos mesmos

Info

Publication number
BR112021010634A2
BR112021010634A2 BR112021010634A BR112021010634A BR112021010634A2 BR 112021010634 A2 BR112021010634 A2 BR 112021010634A2 BR 112021010634 A BR112021010634 A BR 112021010634A BR 112021010634 A BR112021010634 A BR 112021010634A BR 112021010634 A2 BR112021010634 A2 BR 112021010634A2
Authority
BR
Brazil
Prior art keywords
antibodies
antiperiostin
periostin
tumor
cancer
Prior art date
Application number
BR112021010634A
Other languages
English (en)
Inventor
Robert Mcgray Aj
Arif Jetha
Joanne Hulme
Johan Fransson
Original Assignee
Boehringer Ingelheim Io Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Io Canada Inc filed Critical Boehringer Ingelheim Io Canada Inc
Publication of BR112021010634A2 publication Critical patent/BR112021010634A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

anticorpos antiperiostina e usos dos mesmos. a presente invenção refere-se a anticorpos que bloqueiam a função da periostina. também são descritos neste documento seus usos no tratamento do câncer e na modificação das propriedades imunológicas do tumor.
BR112021010634A 2018-12-14 2019-12-13 Anticorpos antiperiostina e usos dos mesmos BR112021010634A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779996P 2018-12-14 2018-12-14
US201962899075P 2019-09-11 2019-09-11
PCT/IB2019/001307 WO2020121059A1 (en) 2018-12-14 2019-12-13 Anti-periostin antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR112021010634A2 true BR112021010634A2 (pt) 2021-11-16

Family

ID=71075443

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021010634A BR112021010634A2 (pt) 2018-12-14 2019-12-13 Anticorpos antiperiostina e usos dos mesmos

Country Status (20)

Country Link
US (1) US20220010003A1 (pt)
EP (1) EP3894439A4 (pt)
JP (2) JP2022513228A (pt)
KR (1) KR20210108972A (pt)
CN (1) CN113631571A (pt)
AU (1) AU2019395887A1 (pt)
BR (1) BR112021010634A2 (pt)
CA (1) CA3120059A1 (pt)
CL (1) CL2021001297A1 (pt)
CO (1) CO2021007444A2 (pt)
CR (1) CR20210310A (pt)
DO (1) DOP2021000113A (pt)
EC (1) ECSP21043288A (pt)
IL (1) IL283890A (pt)
JO (1) JOP20210144A1 (pt)
MA (1) MA54472A (pt)
MX (1) MX2021007043A (pt)
PE (1) PE20211962A1 (pt)
SG (1) SG11202103849TA (pt)
WO (1) WO2020121059A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220062056A (ko) * 2019-09-11 2022-05-13 베링거 잉겔하임 아이오 캐나다 인크. Pd-1 축 억제제 및 항-페리오스틴 항체의 사용에 의한 암 치료 방법
KR20240038198A (ko) 2022-09-15 2024-03-25 한남대학교 산학협력단 인슐린 분비 베타세포 분화 유도 항체 및 이를 유효성분으로 포함하는 대사성 질환 예방 또는 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP2128623B1 (en) * 2006-02-22 2013-06-26 Philogen S.p.A. Vascular tumor markers
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
JP6885606B2 (ja) * 2015-09-18 2021-06-16 アーチ オンコロジー, インコーポレイテッドArch Oncology, Inc. 治療用ｃｄ４７抗体

Also Published As

Publication number Publication date
JP2022513228A (ja) 2022-02-07
WO2020121059A1 (en) 2020-06-18
JOP20210144A1 (ar) 2023-01-30
PE20211962A1 (es) 2021-10-04
CO2021007444A2 (es) 2021-09-30
ECSP21043288A (es) 2021-09-30
IL283890A (en) 2021-07-29
US20220010003A1 (en) 2022-01-13
CN113631571A (zh) 2021-11-09
CA3120059A1 (en) 2020-06-18
CR20210310A (es) 2021-11-24
MA54472A (fr) 2022-03-23
JP2023139243A (ja) 2023-10-03
KR20210108972A (ko) 2021-09-03
SG11202103849TA (en) 2021-05-28
MX2021007043A (es) 2021-08-11
EP3894439A1 (en) 2021-10-20
DOP2021000113A (es) 2021-09-30
EP3894439A4 (en) 2022-11-30
CL2021001297A1 (es) 2022-01-07
AU2019395887A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
CO2020014345A2 (es) Anticuerpos específicos para gucy2c y sus usos
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
CY1123977T1 (el) Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου
EA201892294A1 (ru) Антитела и композиции против tim-3
EA202090104A1 (ru) Молекулы антител к cd73 и пути их применения
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
GEP20237466B (en) Methods of inhibiting angiogenesis in patient
BR112018015485A2 (pt) imunoglobulina fabs-in-tandem e usos da mesma
BR112019011450A2 (pt) células naturais killer modificadas e uso das mesmas
EA202091540A1 (ru) Антитела к lilrb2
CR20170600A (es) Anticuerpos del factor x1 y métodos de uso
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
CO2020013089A2 (es) Anticuerpos contra mica y/o micb y sus usos
CL2021000258A1 (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
CO2018010827A2 (es) Anticuerpos anti-factor bb del complemento y usos de estos
CO2019003759A2 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
MX2020009130A (es) Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos.
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos
CO2021014768A2 (es) Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo
CY1124492T1 (el) 7-υποκατεστημενα 1-αρυλο-ναφθυριδιν-3-καρβοξαμιδια και η χρηση αυτων
BR112021010634A2 (pt) Anticorpos antiperiostina e usos dos mesmos
BR112018009004A2 (pt) conjugados anti-cd3-folato e seus usos
TR201908138T4 (tr) Bir anti-her2 antikoru ilaç konjügatı ve bir bcl-2 inhibitörü ile kombinasyon terapisi.
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения